- Home
- EPOW vs AKTX Comparison
EPOW vs AKTX Comparison
Compare EPOW & AKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EPOW
- AKTX
- Stock Information
- Founded
- EPOW 2014
- AKTX N/A
- Country
- EPOW China
- AKTX United States
- Employees
- EPOW N/A
- AKTX N/A
- Industry
- EPOW Business Services
- AKTX Biotechnology: Pharmaceutical Preparations
- Sector
- EPOW Consumer Discretionary
- AKTX Health Care
- Exchange
- EPOW Nasdaq
- AKTX Nasdaq
- Market Cap
- EPOW 24.1M
- AKTX 26.5M
- IPO Year
- EPOW 2021
- AKTX N/A
- Fundamental
- Price
- EPOW $1.33
- AKTX $0.94
- Analyst Decision
- EPOW
- AKTX Strong Buy
- Analyst Count
- EPOW 0
- AKTX 2
- Target Price
- EPOW N/A
- AKTX $3.30
- AVG Volume (30 Days)
- EPOW 5.6M
- AKTX 468.3K
- Earning Date
- EPOW 05-15-2025
- AKTX 11-18-2025
- Dividend Yield
- EPOW N/A
- AKTX N/A
- EPS Growth
- EPOW N/A
- AKTX N/A
- EPS
- EPOW N/A
- AKTX N/A
- Revenue
- EPOW $64,997,741.00
- AKTX N/A
- Revenue This Year
- EPOW N/A
- AKTX N/A
- Revenue Next Year
- EPOW N/A
- AKTX N/A
- P/E Ratio
- EPOW N/A
- AKTX N/A
- Revenue Growth
- EPOW 44.28
- AKTX N/A
- 52 Week Low
- EPOW $0.70
- AKTX $0.57
- 52 Week High
- EPOW $1.86
- AKTX $3.15
- Technical
- Relative Strength Index (RSI)
- EPOW 59.65
- AKTX 50.70
- Support Level
- EPOW $1.22
- AKTX $0.91
- Resistance Level
- EPOW $1.48
- AKTX $1.11
- Average True Range (ATR)
- EPOW 0.23
- AKTX 0.14
- MACD
- EPOW 0.01
- AKTX 0.00
- Stochastic Oscillator
- EPOW 49.53
- AKTX 41.19
About EPOW Sunrise New Energy Co. Ltd
Sunrise New Energy Co Ltd is engaged in the manufacturing and sale of graphite anode material for EVs and other lithium-ion batteries. The Company's joint venture is in the construction of a manufacturing plant in Guizhou Province. The plant runs on inexpensive electricity from renewable sources that enables the group to be a low-cost and low environmental impact producer of graphite anode material, Its products include GS-1, GS-2, GS-3, GZD-1, GLD-1, and GZ-1.
About AKTX Akari Therapeutics plc ADS
Akari Therapeutics PLC is an oncology company developing next-generation antibody-drug conjugates (ADCs) designed around novel, proprietary cancer-killing toxins (payloads). The company believes these novel payloads may have the potential to transform the efficacy and safety outcomes of ADCs as cancer therapies beyond options that are currently available or in development. Its lead product candidate is AKTX-101, a preclinical stage Trop2-targeting ADC that combines PH1 with the Trop2 antibody, which is expressed in the highest number of solid tumor cancer types, including lung, breast, colon and prostate.